{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T23:35:32Z","timestamp":1788910532015,"version":"build-2803163510"},"reference-count":121,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2021,10,6]],"date-time":"2021-10-06T00:00:00Z","timestamp":1633478400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["CA A Cancer J Clinicians"],"published-print":{"date-parts":[[2022,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Chimeric antigen receptor (CAR) T\u2010cell therapy is a promising immunotherapeutic treatment concept that is changing the treatment approach to hematologic malignancies. The development of CAR T\u2010cell therapy represents a prime example for the successful bench\u2010to\u2010bedside translation of advances in immunology and cellular therapy into clinical practice. The currently available CAR T\u2010cell products have shown high response rates and long\u2010term remissions in patients with relapsed\/refractory acute lymphoblastic leukemia and relapsed\/refractory lymphoma. However, CAR T\u2010cell therapy can induce severe life\u2010threatening toxicities such as cytokine release syndrome, neurotoxicity, or infection, which require rapid and aggressive medical treatment in the intensive care unit setting. In this review, the authors provide an overview of the state\u2010of\u2010the\u2010art in the clinical management of severe life\u2010threatening events in CAR T\u2010cell recipients. Furthermore, key challenges that have to be overcome to maximize the safety of CAR T cells are discussed.<\/jats:p>","DOI":"10.3322\/caac.21702","type":"journal-article","created":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T17:50:16Z","timestamp":1633715416000},"page":"78-93","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":60,"title":["Critical care management of chimeric antigen receptor T\u2010cell therapy recipients"],"prefix":"10.3322","volume":"72","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2351-7294","authenticated-orcid":false,"given":"Alexander","family":"Shimabukuro\u2010Vornhagen","sequence":"first","affiliation":[{"name":"Department I of Internal Medicine University of Cologne, Faculty of Medicine and University Hospital Cologne Cologne Germany"},{"name":"Intensive Care in Hematologic and Oncologic Patients (iCHOP) Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boris","family":"B\u00f6ll","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine University of Cologne, Faculty of Medicine and University Hospital Cologne Cologne Germany"},{"name":"Intensive Care in Hematologic and Oncologic Patients (iCHOP) Cologne Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Schellongowski","sequence":"additional","affiliation":[{"name":"Intensive Care in Hematologic and Oncologic Patients (iCHOP) Cologne Germany"},{"name":"Department of Medicine I Intensive Care Unit 13i2, Comprehensive Cancer Center Center of Excellence in Medical Intensive Care (CEMIC) Medical University of Vienna Vienna Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Valade","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit St Louis Teaching Hospital Public Assistance Hospitals of Paris Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Metaxa","sequence":"additional","affiliation":[{"name":"Department of Critical Care King's College Hospital National Health Service Foundation Trust London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elie","family":"Azoulay","sequence":"additional","affiliation":[{"name":"Medical Intensive Care Unit St Louis Teaching Hospital Public Assistance Hospitals of Paris Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"von Bergwelt\u2010Baildon","sequence":"additional","affiliation":[{"name":"Intensive Care in Hematologic and Oncologic Patients (iCHOP) Cologne Germany"},{"name":"Department of Medicine III University Hospital Ludwig\u2010Maximilians University Munich Munich Germany"},{"name":"Munich Comprehensive Cancer Center University Hospital Ludwig\u2010Maximilians University Munich Munich Germany"},{"name":"Bavarian Center for Cancer Research Munich Germany"},{"name":"Nine\u2010i Multinational Research Network, Service de M\u00e9decine Intensive et R\u00e9animaton M\u00e9dicale, H\u00f4pital Saint\u2010Louis France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2021,10,6]]},"reference":[{"key":"e_1_2_5_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_2_5_3_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002842"},{"key":"e_1_2_5_4_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_2_5_5_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0608138103"},{"key":"e_1_2_5_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709919"},{"key":"e_1_2_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03458"},{"key":"e_1_2_5_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_5_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1708566"},{"key":"e_1_2_5_10_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1914347"},{"key":"e_1_2_5_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2030164"},{"key":"e_1_2_5_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817226"},{"key":"e_1_2_5_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.06.020"},{"key":"e_1_2_5_14_1","first-page":"1979","article-title":"Innovative strategies to advance CAR T cell therapy for solid tumors","volume":"10","author":"Huang M","year":"2020","journal-title":"Am J Cancer Res"},{"key":"e_1_2_5_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-018-0042-2"},{"key":"e_1_2_5_16_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02711"},{"key":"e_1_2_5_17_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21351"},{"key":"e_1_2_5_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00003246-200210000-00014"},{"key":"e_1_2_5_19_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0087779"},{"key":"e_1_2_5_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002053"},{"key":"e_1_2_5_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(21)00060-0"},{"key":"e_1_2_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001972"},{"key":"e_1_2_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.016"},{"key":"e_1_2_5_24_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.24.10024"},{"key":"e_1_2_5_25_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-042718-041407"},{"key":"e_1_2_5_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70"},{"key":"e_1_2_5_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"e_1_2_5_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4597"},{"key":"e_1_2_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/d41573-020-00099-9"},{"key":"e_1_2_5_30_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"e_1_2_5_31_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2708"},{"key":"e_1_2_5_32_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0460-5"},{"key":"e_1_2_5_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2019.05.065"},{"key":"e_1_2_5_34_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001837"},{"key":"e_1_2_5_35_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_5_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01467"},{"key":"e_1_2_5_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001159"},{"key":"e_1_2_5_38_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26113"},{"key":"e_1_2_5_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0487-3"},{"key":"e_1_2_5_40_1","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.12871117"},{"key":"e_1_2_5_41_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2019.10.011"},{"key":"e_1_2_5_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awz053"},{"key":"e_1_2_5_43_1","doi-asserted-by":"publisher","DOI":"10.1097\/COC.0000000000000596"},{"key":"e_1_2_5_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2020.02.012"},{"key":"e_1_2_5_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-11-812982"},{"key":"e_1_2_5_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.08.003"},{"key":"e_1_2_5_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0343-9"},{"key":"e_1_2_5_48_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"e_1_2_5_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0041-7"},{"key":"e_1_2_5_50_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00524"},{"key":"e_1_2_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.03279"},{"key":"e_1_2_5_52_1","first-page":"193","article-title":"Patient characteristics and pre\u2010infusion biomarkers of inflammation correlate with clinical outcomes after treatment with the defined composition, CD19\u2010targeted CAR T cell product, JCAR017 [abstract]","volume":"130","author":"Siddiqi T","year":"2017","journal-title":"Blood"},{"key":"e_1_2_5_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2020.07.025"},{"key":"e_1_2_5_54_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0698"},{"key":"e_1_2_5_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_238691"},{"key":"e_1_2_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1319"},{"key":"e_1_2_5_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-1368"},{"key":"e_1_2_5_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.08.022"},{"key":"e_1_2_5_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2019.100596"},{"key":"e_1_2_5_60_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000717"},{"key":"e_1_2_5_61_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.238634"},{"key":"e_1_2_5_62_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010543"},{"key":"e_1_2_5_63_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa121"},{"key":"e_1_2_5_64_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019004000"},{"key":"e_1_2_5_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"e_1_2_5_66_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2018.0073"},{"key":"e_1_2_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.04.008"},{"key":"e_1_2_5_68_1","first-page":"79","article-title":"An international survey on the management of patients receiving CAR T\u2010cell therapy for haematological malignancies on behalf of the Chronic Malignancies Working Party of EBMT","volume":"67","author":"Hayden PJ","year":"2019","journal-title":"Current Res Transl Med"},{"key":"e_1_2_5_69_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aaz3223"},{"key":"e_1_2_5_70_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201810-1945ED"},{"key":"e_1_2_5_71_1","doi-asserted-by":"publisher","DOI":"10.1136\/practneurol-2020-002550"},{"key":"e_1_2_5_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2019.09.037"},{"key":"e_1_2_5_73_1","doi-asserted-by":"publisher","DOI":"10.1017\/S147895151600095X"},{"key":"e_1_2_5_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.10.049"},{"key":"e_1_2_5_75_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.048100"},{"key":"e_1_2_5_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-018-0571-y"},{"key":"e_1_2_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2018.11.002"},{"key":"e_1_2_5_78_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_5_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_5_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_5_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000952"},{"key":"e_1_2_5_82_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.243246"},{"key":"e_1_2_5_83_1","doi-asserted-by":"publisher","DOI":"10.1186\/cc9975"},{"key":"e_1_2_5_84_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.202002-0286LE"},{"key":"e_1_2_5_85_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000035"},{"key":"e_1_2_5_86_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0028"},{"key":"e_1_2_5_87_1","first-page":"705","article-title":"Spotlight on tocilizumab in the treatment of CAR\u2010T\u2010cell\u2013induced cytokine release syndrome: clinical evidence to date","volume":"16","author":"Si S","year":"2020","journal-title":"Ther Clin Risk Manag"},{"key":"e_1_2_5_88_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000191"},{"issue":"1","key":"e_1_2_5_89_1","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1182\/blood.V130.Suppl_1.1547.1547","article-title":"Preliminary results of prophylactic tocilizumab after axicabtagene ciloleucel (Axi\u2010Cel; KTE\u2010C19) treatment for patients with refractory, aggressive non\u2010Hodgkin lymphoma (NHL) [abstract]","volume":"130","author":"Locke FL","year":"2017","journal-title":"Blood"},{"key":"e_1_2_5_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01085-1"},{"key":"e_1_2_5_91_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-19-3685"},{"key":"e_1_2_5_92_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0010-1"},{"key":"e_1_2_5_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcyt.2017.04.001"},{"key":"e_1_2_5_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V128.22.654.654"},{"key":"e_1_2_5_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.089"},{"key":"e_1_2_5_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008865"},{"issue":"3","key":"e_1_2_5_97_1","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/j.bbmt.2019.12.603","article-title":"Earlier steroid use with axicabtagene ciloleucel (Axi\u2010Cel) in patients with relapsed\/refractory large B cell lymphoma (R\/R LBCL) [abstract]","volume":"26","author":"Topp M","year":"2019","journal-title":"Biol Blood Marrow Transplant"},{"key":"e_1_2_5_98_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02477"},{"key":"e_1_2_5_99_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1924370"},{"key":"e_1_2_5_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.04.020"},{"key":"e_1_2_5_101_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-1271"},{"key":"e_1_2_5_102_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2020-0116"},{"key":"e_1_2_5_103_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018028720"},{"key":"e_1_2_5_104_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5907"},{"key":"e_1_2_5_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcrc.2020.02.010"},{"key":"e_1_2_5_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"e_1_2_5_107_1","doi-asserted-by":"publisher","DOI":"10.1002\/cti2.1154"},{"key":"e_1_2_5_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-110164"},{"key":"e_1_2_5_109_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21596"},{"key":"e_1_2_5_110_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020002592"},{"key":"e_1_2_5_111_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"},{"key":"e_1_2_5_112_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-793141"},{"key":"e_1_2_5_113_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1061-7"},{"key":"e_1_2_5_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0329-2"},{"key":"e_1_2_5_115_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.CCM.0000256846.27192.7A"},{"key":"e_1_2_5_116_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1807382"},{"key":"e_1_2_5_117_1","doi-asserted-by":"publisher","DOI":"10.1042\/BST20150240"},{"key":"e_1_2_5_118_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.02079"},{"key":"e_1_2_5_119_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.0035"},{"key":"e_1_2_5_120_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2020.1769109"},{"key":"e_1_2_5_121_1","first-page":"192","article-title":"Economic burden of neurologic toxicities associated with treatment of patients with relapsed or refractory diffuse large B\u2010cell lymphoma in the United States","volume":"13","author":"Broder MS","year":"2020","journal-title":"Am Health Drug Benefits"},{"key":"e_1_2_5_122_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020003531"}],"container-title":["CA: A Cancer Journal for Clinicians"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21702","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.3322\/caac.21702","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.3322\/caac.21702","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T08:54:58Z","timestamp":1762332898000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.3322\/caac.21702"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,6]]},"references-count":121,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["10.3322\/caac.21702"],"URL":"https:\/\/doi.org\/10.3322\/caac.21702","archive":["Portico"],"relation":{},"ISSN":["0007-9235","1542-4863"],"issn-type":[{"value":"0007-9235","type":"print"},{"value":"1542-4863","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,6]]},"assertion":[{"value":"2021-03-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-07-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-10-06","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}